WebOct 29, 2024 · 当社は、このたび、Moderna社の新型コロナウイルス感染症ワクチン候補であるmRNA-1273を、2024年前半より、5,000万回の接種分を輸入し、日本において供 … WebApr 11, 2024 · その結果、血透析患者におけるBNT162b2ワクチンに対する液性免疫反応は、3回目接種までは大幅な上昇反応を示すものの4回目接種では有意に鈍化することを …
Antibodies elicited by mRNA-1273 vaccination bind more broadly ... - PubMed
WebApr 12, 2024 · 以前、Bacille Calmette-Guérinワクチンの製造(培養増殖)のばらつきが、このワクチンの重要な免疫学的効果に影響を与えることが示された7。 また、同じ日 … WebmRNA-1273.617. Phase 2. Moderna rights:Worldwide. COVID-19 vaccine Beta variant + wild-type. mRNA-1273.211. Phase 2. Moderna rights:Worldwide. COVID-19 vaccine Beta + Delta variant. mRNA-1273.213. Phase 2. Moderna rights:Worldwide. COVID-19 vaccine Next generation (2-5 ºC) mRNA-1283. Phase 2. Moderna rights:Worldwide. Flu vaccine. the town the movie
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in
WebApr 26, 2024 · This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT) and in healthy adult participants. The primary goal of the study is to evaluate the safety of mRNA-1273 … WebThe EUA request includes safety and efficacy data from an ongoing Phase 3 randomized, double-blinded and placebo-controlled trial of mRNA-1273 in approximately 30,400 … WebJan 13, 2024 · The corresponding excess risk (BNT162b2 vs. mRNA-1273) of documented infection over 12 weeks of follow-up in a period marked by delta-variant predominance was 6.54 events per 1000 persons (95% CI, -2.58 to 11.82). Conclusions: The 24-week risk of Covid-19 outcomes was low after vaccination with mRNA-1273 or BNT162b2, although … the town the weeknd